Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from TrivarX Limited ( (AU:TRI) ) is now available.
TrivarX Limited has announced a significant advancement in its operations through a collaboration with the US Department of Veterans Affairs and the Greater Los Angeles Veterans Research and Education Foundation. This partnership involves a clinical trial to evaluate TrivarX’s single-channel ECG algorithm for mental health screening, which could lead to commercialization opportunities. Additionally, the company has secured $2.25 million in funding to support its initiatives, including the pivotal trial design for its MEB-001 technology, which is a step closer to FDA approval. These developments position TrivarX to enhance its industry standing and offer improved mental health care solutions.
More about TrivarX Limited
TrivarX Limited is a company operating in the healthcare technology industry, focusing on innovative mental health solutions. The company specializes in developing AI-backed algorithms for mental health screening, particularly in sleep study patients, and is actively involved in clinical trials and regulatory processes to expand its market presence.
Technical Sentiment Signal: Buy
Current Market Cap: $4.4M
For an in-depth examination of TRI stock, go to TipRanks’ Stock Analysis page.